Company Report
Last edited 3 years ago
PerformanceCommunity EngagementCommunity Endorsement
ranked
#228
Performance (77m)
-0.3% pa
Followed by
27
Straws
Sort by:
Recent
Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.
#ASX Announcements
stale
Added 3 years ago

After lots of discussion recently on the emerging lung screening side of the business, VHT today announced their biggest sales contract win to date $430000 ARR.  Positive news, hoping the comment about momentum is reflected in more of these announcements.  Revenue now the key for VHT.

Volpara signs major contract with leading US outpatient diagnostic imaging provider; largest contract signed to date

Highlights:

  • Five-year, US$2.15M contract representing US$430K Annual Recurring Revenue (ARR)

  • Under the agreement, Volpara® Patient HubTM will replace multiple legacy patient tracking systems

  • Agreement also includes Volpara® RiskTM and ScorecardTM, underscoring the value of the Volpara® Breast Health PlatformTM

    Wellington, NZ, 5 October 2021: Volpara Health Technologies Limited (“Volpara,” “the Group,” or “the Company”; ASX:VHT), a global health technology software leader providing an integrated platform for the delivery of personalised breast care, has entered into its highest-value contract to date through a five-year, US$2.15M contract with a leading US outpatient diagnostic imaging provider, representing US$430K ARR.

    Volpara will install its Patient Hub software across the customer’s extensive network of imaging centres located in 11 states to provide a standardised patient tracking platform that incorporates Volpara Risk and Scorecard—the most clinically validated density software available today. This will enable the customer to accurately triage each patient into the appropriate personalised breast cancer screening pathway.

    Dr Ralph Highnam, Group CEO of Volpara, said: “While we would not normally announce individual deals, this is Volpara’s highest-value contract signed to date. We are experiencing tremendous momentum for our platform in the market as we bring together best-of-breed patient tracking, risk assessment, and density scoring to allow our customers to provide their patients with the individualised care they deserve. Our platform provides both Volpara and our customers with a significant advantage and is enabling us to seek out opportunities that did not exist even a couple of years ago.”